Insilico Medicine
Insilico Medicine develops an AI platform for drug development to treat cancer and age-related diseases. It pioneered the applications of the generative adversarial networks (GANs), reinforcement learning, transfer learning, and meta-learning for the generation of novel molecular structures for the diseases with known and unknown targets, and, unlike the other companies in the field, is developing the end-to-end pipeline covering every step of drug discovery, clinical trials analysis, and digital medicine. Insilico Medicine is pursuing internal drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson's Disease, Alzheimer's Disease, ALS, diabetes, sarcopenia, and aging. Through a partnership with Life Extension, the company launched a range of nutraceutical products, which were compounded using advanced bioinformatics techniques and deep learning approaches. It also provides a range of consumer-facing applications including Young.AI.
Domain
insilico.com
Country
United StatesIndustry
Artificial Intelligence (AI)Employees
101-250
Last Funding
$123.0M
Founded
2013
Tech Stack (7 technologies)
Frequently Asked Questions
What technologies does Insilico Medicine use?+
Insilico Medicine uses 7 technologies including Google Analytics, Google Tag Manager, Hammer.js.
What industry is Insilico Medicine in?+
Insilico Medicine operates in the Artificial Intelligence (AI) industry.
Where is Insilico Medicine based?+
Insilico Medicine is headquartered in United States.
Explore More
Need this data at scale?
Get ready-to-use datasets: companies, technologies, and tech adoption signals across 3M+ websites.
Browse DatasetsData last updated: June 2026